PRINCETON, N.J. and SUZHOU, China, March 27, 2025 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that it will debut the preclinical data of a novel FGFR2b-targeting ADC as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from April 25-30, 2025. This ADC, conjugated with a topoisomerase I inhibitor payload using glycosyltransferase-mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models.

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

Abstract Title: Characterization of novel humanized FGFR2b antibody-based ADCs site-specifically conjugated with topoisomerase I inhibitor payload in preclinical tumor models

Published Abstract Number: 4769

Session Category: Immunology

Session Title: Antibodies and Antibody-Drug Conjugates

Date and Time: 4/29/2025 9:00:00 AM-12:00:00 PM (CST)

Location: Poster Section 36

Poster Board Number: 5

About Transcenta

Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, US and Europe. Transcenta is developing 14 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.